ArticleJournal of advanced research2026
Integrating molecular generation and fingerprints transferring for single-molecule theranostics targeting endoplasmic reticulum stress.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrecise diagnosis and treatment of diseases necessitate quantitative visualization and modulation of subcellular structures. The endoplasmic reticulum (ER), as one of the most essential organelles, presents a complex target due to its intricate morphology and diverse cellular roles. Regulating ER stress offers a promising strategy for treating diseases such as tumors. However, achieving accurate targeting and therapeutic intervention at the subcellular level remains a significant challenge. Thus, there is an urgent need for theranostic agents that can precisely target and modulate ER stress.
objectivesThis study proposes a novel AI-driven dual-targeting strategy combining "passive + active" mechanisms to efficiently design molecules that resolve the balance between passive ER enrichment and precise modulation. We aim to design multifunctional theranostic molecules that precisely target Grp78, a key biomarker of ER stress, at the atomic level, enabling concurrent imaging and modulation of ER stress.
methodsA machine learning (ML)-based molecular fingerprints transfer method was developed for passive targeting based on identified subcellular targeting substructures. Meanwhile, a deep learning (DL)-based 3D molecular generation model, PM-1, was designed for active targeting through specific receptor interactions. By transferring key fingerprints and fluorescent motifs into PM-1-generated molecules, desired theranostic agents were produced. Their key properties were validated via dynamic simulations and quantitative calculations, followed by wet experiments.
resultsGuided by these strategies, we identified unreported ER-targeting rules by discovering key passive-targeting fingerprints derived from ML models, and generated diverse new structures with high affinity binding to Grp78. We successfully synthesized ABT-CN2, a multidimensional fluorescent agent that demonstrates cost-effective chemical structure (molecular weight <400), robust targeting capability (Pearson's correlation coefficient = 0.93), and potential antitumor activity (IC
conclusionThis work presents a new paradigm for the intelligent design of fluorescent molecular probes with precise organelle-targeting capabilities for integrated diagnosis and therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.